GH / Guardant Health Clocks 22% Jump In Q1 Revenues, Reiterates FY22 Guidance

Guardant Health's various products are all designed to help physicians and patients fight cancer. The company's revenue growth has been good, but its more_horizontal

Guardant Health (GH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help th more_horizontal

Analysts at both Bernstein and Piper Sandler had good things to say about Guardant Health this week. Shares of the precision oncology company had plun more_horizontal

Guardant Health stock has lost half its value over the past year. That's the bad news. more_horizontal

The average of price targets set by Wall Street analysts indicates a potential upside of 42.1% in Guardant Health (GH). While the effectiveness of thi more_horizontal

Guardant Health, Inc. (NASDAQ:GH ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Carrie Mendivil - IR Helmy Eltoukhy more_horizontal

Guardant Health (GH) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $1.25. This compares to loss o more_horizontal

Guardant Health's share price has been volatile over the past year, but with strong clinical volume growth, the company presents an interesting invest more_horizontal